Related Experiment Video

Updated: Aug 11, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

miR-640 Enhances Abemaciclib Sensitivity by Suppressing CDK Inhibitor Resistance-Associated Genes in Breast Cancer

Ismail Mert Alkac1, Cigir Biray Avci1

  • 1Department of Medical Biology, Ege University Medical School, İzmir, Turkey.

Journal of Cellular and Molecular Medicine
|August 10, 2026
PubMed

Insights

MicroRNA-640 (miR-640) shows promise as a tumor suppressor in breast cancer. It resensitizes cells to CDK4/6 inhibitors by downregulating resistance genes, enhancing apoptosis and reducing metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • CDK4/6 inhibitors are crucial in breast cancer treatment but resistance limits efficacy.
  • MicroRNAs (miRNAs) are key regulators of gene expression with therapeutic potential.
  • Identifying novel therapeutic targets to overcome resistance is essential.

Purpose of the Study:

  • To investigate miR-640's role in downregulating CDK4/6 inhibitor resistance genes.
  • To evaluate the anti-cancer effects of miR-640, alone and with abemaciclib.
  • To explore miR-640's impact on apoptosis, metastasis, and proliferation in breast cancer cells.

Main Methods:

  • Bioinformatic analysis (GSE126125, miRDB, TargetScan, TargetMiner) to identify miR-640 targets.
  • In vitro assays (MTT, Annexin V, cell cycle, wound healing) in MCF7 and MDA-MB-231 cells.
  • Quantitative RT-qPCR to measure target gene expression after miR-640 transfection.

Main Results:

  • miR-640 significantly downregulated key resistance genes (e.g., CDK4/6, CDKN2B, AURKA).
  • Combination therapy (miR-640 + abemaciclib) enhanced apoptosis and inhibited migration.
  • miR-640 induced cell line-specific cell cycle arrest (S/G2/M in MCF7, G0/G1 in MDA-MB-231).

Conclusions:

  • miR-640 acts as a tumor suppressor by targeting resistance pathways.
  • miR-640 resensitizes breast cancer cells to CDK4/6 inhibitors like abemaciclib.
  • miR-640 represents a promising strategy for combination therapy in breast cancer.
Keywords:
CDK4/6 inhibitor resistanceabemaciclibbreast cancergene silencingmiR‐640

More Related Videos

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...